Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro

NCT03341520 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT03341520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03341520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro
Lead sponsor
Heidelberg University
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2018
Completion date
March 14, 2024
Enrollment
89 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

stage i follicular lymphoma grade 1, stage ii follicular lymphoma grade 2, stage ii grade 1 follicular lymphoma, stage ii grade 2 follicular lymphoma